Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Imatinib Mesylate
(IMATINIB MESYLATE)Orphan drugstandardApotex Corp
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Rydapt
(RYDAPT)Orphan drugstandardNovartis Pharmaceuticals Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays hav...
Maryam Fouladi, MD
COG Phase I Consortium
📍 COLUMBUS, OH
Rachael Easton, MD, Ph.D., FNP-BC
Cogent Biosciences, Inc.
📍 TROY, MI
Denise Casey, M.D., M.D
MacroGenics
📍 ROCHESTER, NY
Jason Gotlib, M.D., M.S
Stanford University Hospitals and Clinics
📍 PALO ALTO, CA
Jason Robert Gotlib, M.D., M.S
Stanford University
📍 PALO ALTO, CA
John Deeken, MD
AIDS Associated Malignancies Clinical Trials Consortium
📍 FAIRFAX, VA